Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.

Given the evolving landscape of combination therapies for frontline treatment of advanced renal cell carcinoma, we read with great enthusiasm the manuscript by McGregor and colleagues [ [1] McGregor B. Geynisman D.M. Burotto M. et al. A matching-adjusted indirect comparison of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma. Eur Urol Oncol. 2023; (In press)https://doi.org/10.1016/j.euo.2023.01.012 Abstract Full Text Full Text PDF Google Scholar ]. Studies reporting on health-related quality of life (HRQoL) are critical in helping to identify optimal drug combinations, and this well-written analysis compares HRQoL endpoints from two randomized controlled trials, KEYNOTE-426 [ [2] Rini B.I. Plimack E.R. Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019; 380: 1116-1127https://doi.org/10.1056/NEJMoa1816714 Crossref PubMed Scopus (1986) Google Scholar ] and CheckMate-9ER [ [3] Choueiri T.K. Powles T. Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021; 384: 829-841https://doi.org/10.1056/NEJMoa2026982 Crossref PubMed Scopus (743) Google Scholar ].